• Necrostatin 2: Precision Tools for Dissecting Necroptosis Me

  2026-05-27

  Explore how Necrostatin 2 (Nec-2) enables rigorous analysis of necroptosis pathways and RIPK2 signaling in disease models. This article delivers advanced, practical insights for designing robust experiments beyond conventional necroptosis inhibition studies.

• Alternariol: Mechanistic Insights and Translational Strategi

  2026-05-27

  Alternariol (AOH) is increasingly recognized as a pivotal mycotoxin in food safety and liver disease research. This thought-leadership article synthesizes emerging mechanistic findings with actionable guidance for translational researchers, highlighting how AOH drives hepatic fibrosis and apoptosis, the metabolic pathways involved, and the new opportunities for intervention and risk assessment. Drawing on recent omics-based studies and protocol advances, it positions APExBIO’s Alternariol as an essential tool for advancing mycotoxin research beyond traditional assays.

• Telomerase Inhibition Redefined: BIBR 1532 for Translational

  2026-05-26

  This article offers translational researchers a mechanistic and strategic perspective on leveraging BIBR 1532—a selective telomerase inhibitor—for cancer research. By integrating the latest literature, benchmarking against emerging telomere-targeting strategies, and detailing actionable protocols, it positions BIBR 1532 as a pivotal tool for dissecting telomerase-driven malignancies and designing next-generation oncology workflows.

• Angiotensin II in Applied Hypertension and Vascular Research

  2026-05-26

  Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) is indispensable for modeling hypertension, vascular remodeling, and aortic aneurysm in both in vitro and in vivo studies. This article details advanced experimental workflows, protocol refinements, and troubleshooting strategies leveraging APExBIO’s Angiotensin II, translating the latest reference findings into practical research guidance.

• Streamlining Macrolide Antibiotic Profiles via 3-O-Acyltrans

  2026-05-25

  This study details the genetic refinement of Streptomyces spiramyceticus to produce a simplified, single-component macrolide antibiotic profile by disrupting the 3-O-acyltransferase gene. The results demonstrate a practical route to reduce the complexity of multi-component antibiotics, with implications for production and quality control in antibacterial agent development.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-05-25

  This study reveals that naturally occurring angiotensin peptides, including fragments such as Angiotensin 1/2 (5-7), significantly enhance the binding of SARS-CoV-2 spike protein to human cellular receptors, particularly AXL. These findings advance our understanding of viral pathogenesis and suggest new considerations for renin-angiotensin system research in the context of COVID-19.

• Mutant-Specific Activation of p53Y220C via Chemically Induce

  2026-05-24

  The referenced study details the discovery of TRAP-1, a small molecule inducer that specifically activates the mutant p53Y220C protein by promoting ternary complex formation with BRD4, restoring transcriptional function. These findings demonstrate a novel strategy to reactivate dysfunctional tumor suppressors, with significant implications for targeted cancer therapy.

• NADPH Oxidase-Derived ROS Activate LTCC in Neonatal Rat Arte

  2026-05-23

  This study reveals that NADPH oxidase-derived reactive oxygen species (ROS) drive arterial contraction in early postnatal rats by activating L-type voltage-gated Ca2+ channels (LTCC), rather than canonical Rho-kinase, PKC, or Src-kinase pathways. These results refine our understanding of age-dependent vascular tone control and suggest new directions for neonatal cardiovascular research.

• FBXO22 Degraders and 2-PCA Ligands: Expanding TPD Toolkits

  2026-05-22

  This study introduces potent chemical probes for targeted protein degradation (TPD) via FBXO22, a cancer-associated E3 ubiquitin ligase. By identifying AHPC(Me)-C6-NH2 as a selective FBXO22 degrader and 2-pyridinecarboxyaldehyde (2-PCA) as a novel recruitment ligand, the work broadens the strategies available for precise protein elimination in cellular models.

• Anlotinib in Intra-Abdominal Desmoplastic Small Round Cell T

  2026-05-22

  This article reviews a reference case study demonstrating anlotinib hydrochloride’s clinical impact in treating metastatic intra-abdominal desmoplastic small round cell tumor (IADSRCT)—a rare, aggressive malignancy with poor prognosis. The findings highlight the promise of multi-target tyrosine kinase inhibition in refractory sarcomas and outline implications for angiogenesis-focused cancer research.

• Glutamate Receptor Blockade Mitigates Soman-Induced Neurotox

  2026-05-21

  The referenced study demonstrates that dual-targeting glutamate receptor antagonism, specifically via IEM-1925, provides robust antiseizure, neuroprotective, and cognitive benefits in a rat model of soman-induced status epilepticus. These findings highlight the translational potential of selective AMPA receptor blockade for neuroprotection in organophosphorus nerve agent exposure.

• Anlotinib Hydrochloride: Potent VEGFR2 Inhibition in Tumor A

  2026-05-21

  The reference study establishes anlotinib hydrochloride as a highly potent and selective inhibitor of VEGFR2, demonstrating superior anti-angiogenic activity compared to existing small-molecule TKIs. Its capacity to block key steps in endothelial cell migration and neovascularization positions it as a valuable tool for preclinical cancer research and mechanistic angiogenesis studies.

• BAPTA-AM (SKU B4758): Precision Calcium Chelation for Reliab

  2026-05-20

  This article delivers scenario-driven, evidence-backed guidance on overcoming real laboratory challenges using BAPTA-AM (SKU B4758), a cell-permeable calcium chelator. Drawing from recent literature and validated protocols, it empowers biomedical researchers to achieve reproducible results in calcium signaling, apoptosis, and neuroprotection assays. The workflow-centric analysis highlights why BAPTA-AM is the trusted choice for sensitive intracellular calcium regulation.

• Affinity-Purified Goat Anti-Rabbit IgG (H+L): Protocols & Pr

  2026-05-20

  The Affinity-Purified Goat Anti-Rabbit IgG (H+L), Horseradish Peroxidase Conjugated Secondary Antibody from APExBIO sets a new benchmark for sensitive, reproducible signal amplification in immunoassays. This guide unpacks optimized workflows, troubleshooting strategies, and real-world applications in oncology research, directly referencing breakthrough studies on KRASG12V-driven colorectal cancer.

• Synergistic OXPHOS Disruption via LRPPRC Inhibition and Dasa

  2026-05-19

  This study demonstrates that combining LRPPRC inhibition with dasatinib leads to a synergistic and dual blockade of mitochondrial oxidative phosphorylation (OXPHOS) in cancer cells. By targeting both mitochondrial and nuclear-encoded OXPHOS genes, the approach enhances anti-tumor efficacy and provides a mechanistic rationale for tailored combination therapies in OXPHOS-dependent cancers.

16213 records 2/1081 page Previous Next 12345 下5页 Last page